Tevogen says Databricks commissioned to accelerate PredicTcell development

Tevogen (TVGN) announced the commission of Databricks with an aim to accelerate the development of PredicTcell, the company’s proprietary AI-driven target prediction model for precision immunotherapy. “Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and governing data and AI systems. This support should advance PredicTcell’s capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor engagement with those complexes. The efforts will be directed to bring two foundational models to bear based on the company’s revolutionary ExacTcell platform: predicting immunologically active peptides through machine learning and developing a predictive T cell receptor binding model,” Tevogen stated.